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Professor Anthony Clare
Dear Editor – I was most saddened to hear about the death
of Professor Anthony Clare. Like innumerable people he was
extremely helpful to me in many ways since 1973 when he
introduced me to the Maudsley Hospital in London, where I
was shortly after to work. Since then I found him unfailingly
helpful when I approached him about various academic
matters. His contribution to the reducing the stigma of psychi-
atry worldwide has been enormous. I know of no other
psychiatrist who has achieved so much in this area in the
20th century. He will be much missed by everyone.
Michael Fitzgerald
Henry Marsh Professor Child and Adolescent Psychiatry,
Trinity College Dublin, Dublin 2, Ireland
Intra-arterial injection of
zolpidem and substance
misusers
Dear Editors – Hypnotics have long been drugs of abuse by
both substance misusers and patients attending adult psychi-
atric and general practitioner clinics. Zolpidem is licensed for
the short term treatment of insomnia. However, we are seeing
an increasing amount of abuse of zolpidem particularly
among intravenous drug users (IDU).
Zolpidem abusers can take the drug orally, intravenously or
by crushing or snorting it. Zolpidem abuse can occur in those
who use or are prescribed it for longer than is recommended
(four to six weeks) and at doses higher than 10mg-20mg. Its
affects are also enhanced when used with other substances
such as alcohol. Dependence and withdrawal is commonly
seen in chronic users of the drug.3 A case report detailed the
history of a lady who experienced epileptic seizures following
abrupt withdrawal of zolpidem following a history of chronic
use at high doses.1 Other reported side effects include hallu-
cinations, delusions, ataxia, euphoria, impulsivity and amnesia.
Intravenous abuse is particularly hazardous as doses as small
as 5mg can produce serious effects.   
In the Drug Treatment Centre and Advisory Board we have
more recently seen one serious consequence associated
with injection of zolpidem by intravenous drug users (IDU).
Two patients who regularly injected zolpidem developed ‘arte-
rial microspasm’ and this resulted in ‘tissue necrosis and the
possibility of loss of large areas of skin and digits’ according
to their consultant vascular surgeon. 
Both patients had a history of intravenous drug use and
had injected zolpidem a number of times previously. On one
occasion within hours of injecting both patients complained
of severe pain, difficulty weight bearing and a noticeable
change in colour in the skin in one of their feet. One patient
reported that they boiled two tablets of zolpidem and injected
it into their foot, while the other patient reported crushing two
tablets and injecting into their groin. They denied injecting
other illicit substances at the time. 
Both patients presented to hospital within hours of inject-
ing and the onset of symptoms. Duplex scanning revealed
‘severe microvascular spasm secondary to intra-arterial injec-
tion of zolpidem’. One patient required emergency treatment
with intravenous (IV) heparin to prevent irreversible tissue
destruction and loss of digits. The other patient was treated
with an anticoagulant infusion and tinzaparin sodium (Inno-
hep) and was given further anticoagulant treatment for a
month following discharge.
There have been a limited number of papers suggesting an
association between zolpidem and tissue ischaemia. One
published paper reported that microcrystalline cellulose, an
ingredient in zolpidem, acts as a potent embolic agent result-
ing in microvascular embolisation and ischaemia.2
These cases serve to highlight the dangers of intravenous
(IV) substance misuse. We regularly inform patients about the
risks of injecting illicit substances amongst which include
overdose, infective diseases, abscesses, deep venous throm-
bosis and infective endocarditis. However, we should now
highlight the dangers of injecting zolpidem as even a relatively
small dose can produce serious consequences. We would
like to invite your readers for their comment on similar cases
they may have come across within their clinical practice.
Marie Whitty and John O Connor, 
Drug Treatment Centre and Advisory Board
Trinity Court, 
30-32 Pearse Street, 
Dublin 2, Ireland.
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Caffeine and suicide
Dear Editor – In August 2007, the BBC reported the hospi-
talisation of a 17 year old due to accidental overdose1 in the
UK. A 17 year old taking an overdose in the UK is hardly
unusual so what was so interesting about this case that it
sparked the interest of the national media? The reason was
that the offending substance was the world’s most commonly
consumed drug: caffeine. The teenager in question had drunk
seven double measures (thinking they were singles) of
espresso coffee during a single work-shift and was admitted
due to the toxic effects of caffeine. In this instance, the over-
dose was neither intentional nor fatal but the case illustrates
that, despite it ubiquity, caffeine is a chemical not without its
dangers.
Indeed, this was not the first time that the attention of the
British media was enthused by a caffeine overdose. In Janu-
ary 2002, a 20 year chemistry student committed suicide in
Wales after consuming almost four hundred tablets of Pro
Plus,2 a caffeine-containing stimulant popular among
students. The coroner’s verdict confirmed the cause of death
as suicide by caffeine overdose. Later that same year, the UK
press reported the suicide of a 58 year woman who over-
dosed on several hundred Pro Plus tablets which she
consumed with cans of the caffeine-containing energy drink
Red Bull.3 Her blood caffeine levels were found to 776mg/l;
the fatal level of blood caffeine is estimated at around
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